Compare Stocks: IBRX, BIIB, ROIV, and INSM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIIB Biogen	$217.36 +0.1%	$209.75	$135.39 ▼ $225.80	$32.08B	0.17	688,104 shs	629,905 shs
IBRX ImmunityBio	$8.37 +5.8%	$7.78	$1.95 ▼ $12.43	$8.38B	0.04	7.83 million shs	9.15 million shs
INSM Insmed	$125.30 -3.2%	$118.03	$90.39 ▼ $212.75	$28.26B	0.82	1.73 million shs	1.61 million shs
ROIV Roivant Sciences	$41.02 +0.5%	$35.90	$13.81 ▼ $42.50	$29.49B	1.12	8.54 million shs	7.59 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIIB Biogen	0.00%	-1.67%	+3.49%	+9.32%	+49.90%
IBRX ImmunityBio	0.00%	-2.10%	+4.49%	+10.94%	+204.23%
INSM Insmed	0.00%	+2.47%	+4.58%	+32.78%	-11.32%
ROIV Roivant Sciences	0.00%	+16.86%	+12.76%	+35.93%	+189.91%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIIB Biogen	$217.36 +0.1%	$209.75	$135.39 ▼ $225.80	$32.08B	0.17	688,104 shs	629,905 shs
IBRX ImmunityBio	$8.37 +5.8%	$7.78	$1.95 ▼ $12.43	$8.38B	0.04	7.83 million shs	9.15 million shs
INSM Insmed	$125.30 -3.2%	$118.03	$90.39 ▼ $212.75	$28.26B	0.82	1.73 million shs	1.61 million shs
ROIV Roivant Sciences	$41.02 +0.5%	$35.90	$13.81 ▼ $42.50	$29.49B	1.12	8.54 million shs	7.59 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIIB Biogen	0.00%	-1.67%	+3.49%	+9.32%	+49.90%
IBRX ImmunityBio	0.00%	-2.10%	+4.49%	+10.94%	+204.23%
INSM Insmed	0.00%	+2.47%	+4.58%	+32.78%	-11.32%
ROIV Roivant Sciences	0.00%	+16.86%	+12.76%	+35.93%	+189.91%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIIB Biogen	2.58	Moderate Buy	$230.14	5.88% Upside
IBRX ImmunityBio	2.71	Moderate Buy	$14.20	69.65% Upside
INSM Insmed	3.00	Buy	$205.52	64.02% Upside
ROIV Roivant Sciences	2.85	Moderate Buy	$40.63	-0.96% Downside

Current Analyst Ratings Breakdown

Latest IBRX, BIIB, ROIV, and INSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	BIIB Biogen	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$242.00
9/10/2026	BIIB Biogen	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Reduce	$165.00 ➝ $175.00
9/9/2026	ROIV Roivant Sciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$42.00 ➝ $46.00
9/9/2026	ROIV Roivant Sciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$55.00
9/9/2026	ROIV Roivant Sciences	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $55.00
9/8/2026	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$41.00 ➝ $47.00
9/8/2026	ROIV Roivant Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$42.00 ➝ $52.00
9/3/2026	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$225.00 ➝ $245.00
8/28/2026	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$41.00
8/25/2026	ROIV Roivant Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/25/2026	BIIB Biogen	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$240.00 ➝ $260.00

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIIB Biogen	$9.89B	3.25	$22.67 per share	9.59	$124.45 per share	1.75
IBRX ImmunityBio	$113.29M	78.30	N/A	N/A	($0.51) per share	-16.41
INSM Insmed	$606.42M	45.12	N/A	N/A	$3.46 per share	36.21
ROIV Roivant Sciences	$8.26M	3,587.11	N/A	N/A	$7.35 per share	5.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIIB Biogen	$1.29B	$5.65	38.47	13.49	2.40	8.32%	11.18%	6.88%	10/29/2026 (Estimated)
IBRX ImmunityBio	-$351.40M	-$0.97	N/A	N/A	N/A	-598.55%	N/A	-51.65%	11/3/2026 (Estimated)
INSM Insmed	-$1.28B	-$4.11	N/A	48.01	N/A	-76.94%	-123.94%	-44.30%	10/29/2026 (Estimated)
ROIV Roivant Sciences	-$299.77M	-$0.53	N/A	N/A	N/A	-3,534.96%	-22.94%	-21.53%	11/9/2026 (Estimated)

Latest IBRX, BIIB, ROIV, and INSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2026	Q1 2027	ROIV Roivant Sciences	-$0.2996	-$0.26	+$0.0396	-$0.26	$2.06 million	$1.44 million
8/6/2026	Q2 2026	INSM Insmed	-$0.6724	-$0.06	+$0.6124	-$0.06	$395.50 million	$425.49 million
8/4/2026	Q2 2026	IBRX ImmunityBio	-$0.08	-$0.22	-$0.14	-$0.22	$49.70 million	$51.24 million
7/29/2026	Q2 2026	BIIB Biogen	$2.94	$3.60	+$0.66	$0.66	$2.46 billion	$2.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIIB Biogen	0.39	1.87	1.26
IBRX ImmunityBio	N/A	5.72	5.70
INSM Insmed	0.74	3.72	3.40
ROIV Roivant Sciences	N/A	16.72	16.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIIB Biogen	87.93%
IBRX ImmunityBio	8.58%
INSM Insmed	N/A
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
BIIB Biogen	0.25%
IBRX ImmunityBio	66.10%
INSM Insmed	2.10%
ROIV Roivant Sciences	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIIB Biogen	7,500	147.75 million	147.39 million	Optionable
IBRX ImmunityBio	691	1.06 billion	359.28 million	Optionable
INSM Insmed	1,664	218.38 million	213.80 million	Optionable
ROIV Roivant Sciences	721	722.32 million	658.76 million	Optionable

IBRX, BIIB, ROIV, and INSM Headlines

Recent News About These Companies

California State Teachers Retirement System Has $672.45 Million Holdings in Roivant Sciences Ltd. $ROIV

September 14 at 3:27 AM | marketbeat.com

Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants

September 13 at 8:00 AM | seekingalpha.com

Roivant Sciences Ltd. (ROIV)’s Pulmonary Hypertension Breakthrough Could Transform Its Growth Story

September 13 at 6:11 AM | insidermonkey.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Given Average Rating of "Moderate Buy" by Analysts

September 12 at 4:13 AM | marketbeat.com

Arizona State Retirement System Has $4.54 Million Position in Roivant Sciences Ltd. $ROIV

September 12 at 3:43 AM | marketbeat.com

Roivant Sciences (ROIV) Gets a Buy from TD Cowen

September 11 at 11:07 PM | theglobeandmail.com

Health News Round-Up: Latest Breakthroughs and Challenges

September 11 at 8:05 AM | devdiscourse.comD

61,200 Shares in Roivant Sciences Ltd. $ROIV Bought by VIRGINIA RETIREMENT SYSTEMS ET Al

September 11 at 5:03 AM | marketbeat.com

Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILD - Slideshow

September 10, 2026 | seekingalpha.com

Roivant Sciences Ltd. (ROIV) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 10, 2026 | seekingalpha.com

Squarepoint Ops LLC Buys Shares of 475,571 Roivant Sciences Ltd. $ROIV

September 10, 2026 | marketbeat.com

Stock Traders Purchase Large Volume of Call Options on Roivant Sciences (NASDAQ:ROIV)

September 10, 2026 | americanbankingnews.com

Jefferies Financial Group Boosts Roivant Sciences (NASDAQ:ROIV) Price Target to $52.00

September 10, 2026 | americanbankingnews.com

HC Wainwright Raises Roivant Sciences (NASDAQ:ROIV) Price Target to $47.00

September 10, 2026 | americanbankingnews.com

Revolutionary Strides in Healthcare: From Lung Disease Breakthroughs to Fertility Support

September 9, 2026 | devdiscourse.comD

Roivant Sciences Ltd. (ROIV) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

September 9, 2026 | seekingalpha.com

Roivant Reports 56.3% Placebo-Adjusted PVR Reduction In Phase 2 Mosliciguat PH-ILD Study, Starts Phase 3 PHrontier Trial

September 9, 2026 | pulse2.comP

Roivant Sciences' Pulmovant Reports Positive Phase 2 Results for Mosliciguat in PH-ILD

September 9, 2026 | marketscreener.comM

These 2 biotech stocks hit record highs today – what’s driving the rallies?

September 9, 2026 | msn.com

Roivant (ROIV) Soars to All-Time High; Q2 Hedge Fund Holdings Surge 41%

September 8, 2026 | insidermonkey.com

Roivant Sciences Shares Rise on Positive Mid-Stage Trial Results

September 8, 2026 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBRX, BIIB, ROIV, and INSM Company Descriptions

Biogen NASDAQ:BIIB

$217.36 +0.21 (+0.10%)

Closing price 04:00 PM Eastern

Extended Trading

$217.00 -0.36 (-0.17%)

As of 07:48 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

ImmunityBio NASDAQ:IBRX

$8.37 +0.46 (+5.82%)

Closing price 04:00 PM Eastern

Extended Trading

$8.36 -0.01 (-0.12%)

As of 07:59 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Insmed NASDAQ:INSM

$125.30 -4.11 (-3.18%)

Closing price 04:00 PM Eastern

Extended Trading

$125.80 +0.51 (+0.40%)

As of 07:57 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Roivant Sciences NASDAQ:ROIV

$41.02 +0.20 (+0.49%)

Closing price 04:00 PM Eastern

Extended Trading

$40.65 -0.38 (-0.91%)

As of 07:59 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IBRX, BIIB, ROIV, and INSM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IBRX, BIIB, ROIV, and INSM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IBRX, BIIB, ROIV, and INSM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBRX, BIIB, ROIV, and INSM Company Descriptions

Biogen NASDAQ:BIIB

ImmunityBio NASDAQ:IBRX

Insmed NASDAQ:INSM

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IBRX, BIIB, ROIV, and INSM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IBRX, BIIB, ROIV, and INSM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IBRX, BIIB, ROIV, and INSM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBRX, BIIB, ROIV, and INSM Company Descriptions

Biogen NASDAQ:BIIB

ImmunityBio NASDAQ:IBRX

Insmed NASDAQ:INSM

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools